ClinicalTrials.gg
CompletedNCT03590366Updated Sep 16, 2022Results posted

A Study to Determine Safety and Efficacy of B244 in Subjects With Mild to Moderate Rosacea

A Phase 2 interventional study of B244 and Vehicle in Rosacea, sponsored by AOBiome LLC. Completed at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-09-16.

Sponsored by AOBiome LLC · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 145 studies in Rosacea with a site in United States — 8 open to participants now, 9 under way, none of them phase 3. Rosacea · United States.

Enrollment
54th of 137
140 · median 78
Started
2018
with 7 others
Phase 2
35 of 145
4 open now
Registered
103rd of 145
by date

Among the 145 studies in Rosacea with a site in United States, this one is the 54th largest by enrollment of the 137 interventional ones that give a count, is one of 8 that started in 2018, is one of 35 in phase 2, and was the 103rd registered.

Rosacea

233 studies on the registry are indexed under Rosacea; 23 are open to participants now.

Browse Rosacea studies →

Open to participants now

8 of the 145 studies in Rosacea with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 17 Rosacea studies recruiting now, 9 (53%) set no upper age limit and 7 (41%) stop at 75 or younger; 1 takes children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 145 studies in Rosacea with a site in United States, or all of them as a file.
02

Study summary

This is a Prospective, Vehicle Controlled, Double Blind, Multicenter, Randomized Phase II trial, comparing the effect of twice daily B244 application for 8 weeks vs. vehicle application on treatment of mild to moderate rosacea.

Read the detailed description

This is a Prospective, Vehicle Controlled, Double Blind, Multicenter, Randomized Phase II trial, comparing the effect of twice daily B244 application for 8 weeks vs. vehicle application on treatment of mild to moderate rosacea.

At Screening and Baseline all subjects must have Type 1 erythematotelangiectatic rosacea (ETR).

The total duration of the study will be approximately 12 weeks. Participants will report for a Screening visit and if all inclusion criteria are met will undergo a washout period, between 2 days and 4 weeks, depending on current treatment. Subjects will then report for the Baseline visit.

Subjects will come in for visits at Day 7 (Week 1), Day 28 (Week 4), and Day 56 (Week 8). A final visit will be conducted at Day 84 (Week 12).

Efficacy will be assessed using Clinician Erythema Assessment (CEA), Investigator Global Assessment (IGA), Skindex16, and Patient Self-Assessment (PSA).

Blood and urine samples will be collected for standard safety laboratory tests. Participant's safety will be monitored throughout the study.

Investigators plan to enroll approximately 130 subjects.

Randomization will be 1:1 so that equal numbers of subjects will be treated in each arm of the study.

03

Conditions studied

  • Rosacea

Browse trials for

Keywords

  • Type 1 erythematotelangiectatic rosacea
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female subjects ≥18.
  2. A clinical diagnosis of mild to moderate facial rosacea.
  3. In good general health as determined by a thorough medical history, physical examination, clinical chemistry and hematology.
  4. Presence of 3 to 20 inflammatory lesions on the face (i.e. papules/pustules).
  5. A Clinician Erythema Assessment (CEA) score of 2-3 at Screening and at Baseline Visits (prior to the product application).
  6. Mild to Moderate IGA score of 2-3 at Screening and at Baseline Visits (prior to the investigational product application).
  7. Willing to refrain from using any topical or systemic treatments for the treatment of rosacea, other than the investigational product.
  8. Females of with a negative urine pregnancy test (UPT) at Screening and Baseline/Day 1 (prior to the investigational product application).
  9. Ability to comprehend and comply with study procedures.
  10. Agree to commit to participate in the current protocol.
  11. Provide written prior to any study procedure being performed.

Exclusion criteria

Exclusion Criteria:

  1. Female subjects who are pregnant, lactating or who are trying to conceive will be excluded from participation in this study.
  2. Any uncontrolled chronic or serious disease or medical condition that would normally prevent participation in a clinical trial, or, in the judgment of the Investigator, would put the subject at undue risk, or might confound the study assessments (e.g., other dermatological diseases), or might interfere with the subject's participation in the study, (e.g., planned hospitalization during the study).
  3. Particular forms of rosacea (e.g., rosacea conglobata, rosacea fulminans, isolated rhinophyma, isolated pustulosis of the chin, Ocular rosacea Phymatous rosacea, -induced rosacea, severe rosacea including pyoderma faciale) or other concomitant facial dermatoses that are similar to rosacea such as peri-oral dermatitis, demodicidosis, facial keratosis pilaris, seborrheic dermatitis, acute lupus erythematosus, or actinic telangiectasia.
  4. Presence of more than two (2) nodulocystic lesions on the face.
  5. Presence of less than 3 and more than 20 inflammatory lesions on the face (i.e. papules/pustules).
  6. Severe papulopustular rosacea requiring systemic treatment.
  7. Participation at the time of eligibility assessment (Screening) in any other drug or device study or may have participated within 30 days prior to Screening.
  8. Commencement of new hormonal therapy or dose change to hormonal therapy within 30 days prior to baseline. Dose and frequency of use of any hormonal therapy started more than 30 days prior to baseline must remain unchanged throughout the study. Hormonal therapies include, but are not limited to, oral, injected or implanted hormonal methods of or placement of an intrauterine device (IUD) or intrauterine system (IUS) or other forms of hormonal contraception that have comparable efficacy (e.g. vaginal ring or transdermal hormone contraception)
  9. Presence of beard or excessive facial hair at Screening which would interfere with the study treatments or study assessments and refusal to remove for duration of study.
  10. Carcinoid, Pheochromocytoma or other systemic causes of flushing.
  11. Known sensitivity to B244 or its components.
  12. Refusal to submit to blood and urine sampling for laboratory analysis.
  13. Treatment with prohibited medications.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
140 participants (actual)

Study arms

  • Active comparator
    B244

    B244 suspension in 30ml/bottle Subjects will apply a total of 4 pumps of IP per application to the face twice-a-day.

    Biological: B244

  • Placebo comparator
    Vehicle

    Vehicle, 30ml/bottle Subjects will apply a total of 4 pumps of IP per application to the face twice-a-day.

    Biological: Vehicle

Interventions

  • BiologicalB244

    B244 Suspension

  • BiologicalVehicle

    Vehicle suspension

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0

    Safety and tolerability endpoints will consist of all treatment-related adverse events reporting during the study duration.

    Time frame: Baseline to Day 84

Secondary outcomes

  1. Proportion of Subjects With IGA Improvement at Week 8 Relative to Baseline.

    IGA (Investigator's Global Assessment) was used to assess the overall diseases severity on a scale of 0 to 4 (0=clear, 1=almost clear, 2=mild disease, 3=moderate disease, and 4=severe disease). Improvement is defined as at least 1-grade change.

    Time frame: Baseline to Day 56

  2. Proportion of Subjects With CEA Improvement at Week 8 Relative to Baseline.

    Clinical Erythema Assessment (CEA) was used to assess the extent of rosacea on a scale of 0 to 4 (0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe). Improvement is defined as at least 1-grade change.

    Time frame: Baseline to Day 56

  3. Change in IGA From Week 8 to Baseline.

    IGA (Investigator's Global Assessment) was used to assess the overall diseases severity on a scale of 0 to 4 (0=clear, 1=almost clear, 2=mild disease, 3=moderate disease, and 4=severe disease). A higher grade change indicates greater improvement in disease.

    Time frame: Baseline to Day 56

  4. Change in CEA From Week 8 to Baseline.

    Clinical Erythema Assessment (CEA) was used to assess the extent of rosacea on a scale of 0 to 4 (0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe). A higher grade change indicates greater improvement in disease.

    Time frame: Baseline to Day 56

  5. Change in Skindex 16 and Skindex 16 Sub Scores at Week 1, Week 4, Week 8 and Week 12 From Baseline.

    The Skindex 16 questionnaire was assigned to subjects to examine the relationship between the subject's skin health and quality of life. Subjects scored 16 questions from 0 to 6 (0=never bothered, 6=always bothered). Total scores could range between 0 to 96, where a higher score is associated with a worse quality of life.

    Time frame: Baseline to Day 84

  6. Proportion of Subjects With Change in PSA at Week 1, Week 4, Week 8 and Week 12 From Baseline.

    Subjects were asked to perform static ("snap-shot") evaluations of their rosacea-associated facial erythema severity using the Patient Self Assessment scale (PSA) at each study visit, and report the one integer that best describes the overall severity of their facial redness as seen in a mirror at the time of the evaluation on a scale of 0 to 4 (0=no redness, 1=very mild redness, 2=mild redness, 3=moderate redness, 4=severe redness). A higher grade change indicates greater improvement.

    Time frame: Baseline to Day 84

07

Results

Posted Sep 16, 2022

Participant flow

Participant flow — Overall Study
MilestoneB244Vehicle
Started7367
Completed7059
Not completed38
Withdrew: Adverse event03
Withdrew: Lost to follow-up33
Withdrew: Withdrawal by subject02

Outcome measures

PrimaryNumber of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0

Safety and tolerability endpoints will consist of all treatment-related adverse events reporting during the study duration.

Time frame:
Baseline to Day 84
Reported as:
Count of participants · Participants
Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0
ParticipantsB244Vehicle
Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.056
SecondaryProportion of Subjects With IGA Improvement at Week 8 Relative to Baseline.

IGA (Investigator's Global Assessment) was used to assess the overall diseases severity on a scale of 0 to 4 (0=clear, 1=almost clear, 2=mild disease, 3=moderate disease, and 4=severe disease). Improvement is defined as at least 1-grade change.

Time frame:
Baseline to Day 56
Reported as:
Count of participants · Participants
Proportion of Subjects With IGA Improvement at Week 8 Relative to Baseline.
ParticipantsB244Vehicle
Proportion of Subjects With IGA Improvement at Week 8 Relative to Baseline.5138
SecondaryProportion of Subjects With CEA Improvement at Week 8 Relative to Baseline.

Clinical Erythema Assessment (CEA) was used to assess the extent of rosacea on a scale of 0 to 4 (0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe). Improvement is defined as at least 1-grade change.

Time frame:
Baseline to Day 56
Reported as:
Count of participants · Participants
Proportion of Subjects With CEA Improvement at Week 8 Relative to Baseline.
ParticipantsB244Vehicle
Proportion of Subjects With CEA Improvement at Week 8 Relative to Baseline.4938
SecondaryChange in IGA From Week 8 to Baseline.

IGA (Investigator's Global Assessment) was used to assess the overall diseases severity on a scale of 0 to 4 (0=clear, 1=almost clear, 2=mild disease, 3=moderate disease, and 4=severe disease). A higher grade change indicates greater improvement in disease.

Time frame:
Baseline to Day 56
Reported as:
Count of participants · Participants
Change in IGA From Week 8 to Baseline.
ParticipantsB244Vehicle
Week 8 1-Grade Change3426
Week 8 2-Grade Change1410
Week 8 3-Grade Change32
SecondaryChange in CEA From Week 8 to Baseline.

Clinical Erythema Assessment (CEA) was used to assess the extent of rosacea on a scale of 0 to 4 (0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe). A higher grade change indicates greater improvement in disease.

Time frame:
Baseline to Day 56
Reported as:
Count of participants · Participants
Change in CEA From Week 8 to Baseline.
ParticipantsB244Vehicle
Week 8 1-Grade Change3427
Week 8 2-Grade Change1410
Week 8 3-Grade Change11
SecondaryChange in Skindex 16 and Skindex 16 Sub Scores at Week 1, Week 4, Week 8 and Week 12 From Baseline.

The Skindex 16 questionnaire was assigned to subjects to examine the relationship between the subject's skin health and quality of life. Subjects scored 16 questions from 0 to 6 (0=never bothered, 6=always bothered). Total scores could range between 0 to 96, where a higher score is associated with a worse quality of life.

Time frame:
Baseline to Day 84
Reported as:
Mean · score on a scale
Change in Skindex 16 and Skindex 16 Sub Scores at Week 1, Week 4, Week 8 and Week 12 From Baseline.
score on a scaleB244Vehicle
Change from Baseline at Week 1-8.7 ± 12.584-12.4 ± 17.111
Change from Baseline at Week 4-14.5 ± 13.908-18.4 ± 17.418
Change from Baseline at Week 8-21.0 ± 20.878-19.9 ± 20.164
Change from Baseline at Week 12 (EOS)-19.7 ± 22.152-20.6 ± 22.694
SecondaryProportion of Subjects With Change in PSA at Week 1, Week 4, Week 8 and Week 12 From Baseline.

Subjects were asked to perform static ("snap-shot") evaluations of their rosacea-associated facial erythema severity using the Patient Self Assessment scale (PSA) at each study visit, and report the one integer that best describes the overall severity of their facial redness as seen in a mirror at the time of the evaluation on a scale of 0 to 4 (0=no redness, 1=very mild redness, 2=mild redness, 3=moderate redness, 4=severe redness). A higher grade change indicates greater improvement.

Time frame:
Baseline to Day 84
Reported as:
Count of participants · Participants
Proportion of Subjects With Change in PSA at Week 1, Week 4, Week 8 and Week 12 From Baseline.
ParticipantsB244Vehicle
Week 1 — 0-Grade Change4944
Week 1 — 1-Grade Change1919
Week 1 — 2-Grade Change53
Week 1 — 3-Grade Change00
Week 4 — 0-Grade Change2923
Week 4 — 1-Grade Change3630
Week 4 — 2-Grade Change56
Week 4 — 3-Grade Change10
Week 8 — 0-Grade Change2321
Week 8 — 1-Grade Change3124
Week 8 — 2-Grade Change1411
Week 8 — 3-Grade Change33
Week 12 (EOS) — 0-Grade Change2322
Week 12 (EOS) — 1-Grade Change2921
Week 12 (EOS) — 2-Grade Change1514
Week 12 (EOS) — 3-Grade Change32

Adverse events

Collected over Baseline to Week 12.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
B2440/73 (0%)0/73 (0%)19/73 (26%)
Vehicle0/67 (0%)0/67 (0%)12/67 (17.9%)
Most frequent other events
Showing 10 of 36
Most frequent other events
EventB244Vehicle
Application site painGeneral disorders1/733/67
PruritusSkin and subcutaneous tissue disorders3/730/67
Application site drynessGeneral disorders1/732/67
Application site pruritusGeneral disorders0/732/67
HordeolumInfections and infestations2/730/67
Urinary tract infectionInfections and infestations2/730/67
RashSkin and subcutaneous tissue disorders2/731/67
HeadacheNervous system disorders2/731/67
Viral upper respiratory tract infectionInfections and infestations1/731/67
Acute sinusitisInfections and infestations0/731/67

Baseline characteristics

Modified Intent to Treat (mITT) Population: all subjects who all subjects who met all inclusion/exclusion criteria, were randomized, dispensed treatment, and had at least one post-treatment efficacy evaluation.

Age, Continuous
Age, Continuous(years)B244VehicleTotal
Mean50.6 ± 15.09952.4 ± 13.02251.5 ± 14.120
Sex: Female, Male
Sex: Female, Male(Participants)B244VehicleTotal
Female5548103
Male181937
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)B244VehicleTotal
Hispanic or Latino313162
Not Hispanic or Latino423678
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)B244VehicleTotal
American Indian or Alaska Native000
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American112
White7265137
More than one race000
Unknown or Not Reported000
08

Study locations

9 sites
  • Tampa Bay Medical Research
    Clearwater, Florida 33761, United States
  • Veritas Research Corp
    Miami, Florida 33126, United States
  • South Coast Research Center, Inc.
    Miami, Florida 33136, United States
  • FXM Research Corp.
    Miami, Florida 33175, United States
  • FXM Research Miramar
    Miramar, Florida 33027, United States
  • Wake Research Associates, LLC
    Raleigh, North Carolina 27612, United States
  • Paddington Testing Co.
    Philadelphia, Pennsylvania 19103, United States
  • Omega Medical Research
    Warwick, Rhode Island 02886, United States
  • West Houston Clinical Research Service
    Houston, Texas 77055, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2018 to primary completion in Feb 2019, 7 months.

Results were first posted in Sep 2022, 3 years 7 months after primary completion. A results delay was requested in Jul 2020.

Of 20 phase 2 interventional studies under Rosacea, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 16. This study's 7 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2018
First posted
Jul 18, 2018
StartActual
Jul 2, 2018
Primary completionActual
Feb 11, 2019
CompletionActual
Mar 5, 2019
Results delay requested
Jul 28, 2020
Results first posted
Sep 16, 2022
Last update
Sep 16, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03590366
Lead sponsor
AOBiome LLC
Collaborators
bioRASI, LLC
Responsible party
Sponsor
First posted
Jul 18, 2018
Start date
Jul 2, 2018
Primary completion
Feb 11, 2019
Completion
Mar 5, 2019
Results posted
Sep 16, 2022
Last update
Sep 16, 2022

Study contacts

Judith Ng-Cashin, MD
study director · Chief Medical Officer
Spiros Jamas, ScD
study director · AOBiome Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nitrosomonas eutropha D23

Start the discussion